FDA approves bluebird bio’s Zynteglo for treatment of beta-thalassemia
The first and only cell-based gene therapy for the treatment of “adult and pediatric patients with beta-thalassemia who require regular red blood cell transfusions,” […]
FDA approves bluebird bio’s Zynteglo for treatment of beta-thalassemia Read More »